van Laake Linda W, Hassink Rutger, Doevendans Pieter A, Mummery Christine
Hubrecht Laboratory, Interuniversity Cardiology Institute of the Netherlands, Utrecht, the Netherlands.
J Physiol. 2006 Dec 1;577(Pt 2):467-78. doi: 10.1113/jphysiol.2006.115816. Epub 2006 Sep 28.
Of the medical conditions currently being discussed in the context of possible treatments based on cell transplantation therapy, few have received more attention than the heart. Much focus has been on the potential application of bone marrow-derived cell preparations, which have already been introduced into double-blind, placebo-controlled clinical trials. The consensus is that bone marrow may have therapeutic benefit but that this is not based on the ability of bone marrow cells to transdifferentiate into cardiac myocytes. Are there potential stem cell sources of cardiac myocytes that may be useful in replacing those lost or dysfunctional after myocardial infarction? Here, this question is addressed with a review of the recent literature.
在目前基于细胞移植疗法探讨可能治疗方案的医学病症中，很少有比心脏受到更多关注的了。人们的大量注意力集中在骨髓源细胞制剂的潜在应用上，这种制剂已经被引入双盲、安慰剂对照的临床试验。目前的共识是，骨髓可能具有治疗益处，但这并非基于骨髓细胞转分化为心肌细胞的能力。是否存在可能有助于替代心肌梗死后丧失或功能失调的心肌细胞的潜在干细胞来源呢？在此，通过回顾近期文献来探讨这个问题。
